MedTrace Logo

Vaccine Responses in Cancer

NCT06605625 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-10-28

No results posted yet for this study

Summary

The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.

Conditions

  • Viral Vaccines

Interventions

BIOLOGICAL

Influenza vaccination

one annual dose of inactivated influenza vaccine

BIOLOGICAL

SARS-CoV-2 vaccine

dose of SARS CoV2 vaccine

BIOLOGICAL

Zoster Vaccine Recombinant

first and/or second vaccination for shingles (Herpes zoster)

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • E. John Wherry, PhD · Univeristy of Pennsylvania

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2027-10-31
Completion
2028-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06605625 on ClinicalTrials.gov